Mark LaPre

Vice President of Finance at QurAlis Corporation

Speaker

Mark is a graduate from Bentley University (2008) and University of Massachusetts, Isenberg School of Management (2009). Mark started his career in public accounting, spending a total of eleven years at Deloitte and RSM, located in Boston. Following his time in public accounting, Mark joined Karuna Therapeutics in 2019, completing an IPO in the same year. Following the IPO, the company had a successful clinical path and experienced rapid growth, raising almost $2 billion in follow-on offerings, before being acquired by Bristol-Myers Squibb in early 2024. Mark is now the VP Finance at QurAlis Corporation, an early clinical stage company developing precision medicines for ALS and other neurodegenerative diseases.